



901 California Avenue Palo Alto, CA 94304-1104 Main: 650 • 496-6400 FAX: 650 • 496-1200

FAX TRANSMITTAL SHEETNO. OF PAGES (including this page): 8**RECEIVED
CENTRAL FAX CENTER****JUN 01 2004**

TO: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Art Unit: 1646
FAX: (703) 872-9306

OFFICIAL

FROM: Sheela Mohan-Peterson
DATE: June 1, 2004


RE: Docket No.: DX01040K3B
USSN: 10/777,790
Filed: February 11, 2004
Title: Mammalian Cytokines; Related Reagents

Any difficulty with this facsimile, please call: Melanie Lyons at (650) 496-1183

Documents attached:

- Transmittal (1 page)
- Information Disclosure Statement (2 pages)
- Form PTO/SB/08 (4 pages)

I hereby certify that this correspondence is being transmitted by facsimile to the U.S. Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Fax Number (703) 872-9306, on June 1, 2004.


Melanie Lyons

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to DNAX which is confidential and/or legally privileged. The information is intended only for the use of the person or entity named above. If you have received this fax in error, please immediately notify us by telephone or return Fax.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/777,790
Filing Date	02/11/2004
First Named Inventor	Jacqueline C. TIMANS
Art Unit	1646
Examiner Name	
Attorney Docket Number	DX01040K3B

Total Number of Pages in This Submission

8

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Other Enclosures/Remarks: <ul style="list-style-type: none"> Form PTO/SB/08 Fax Transmittal Sheet 		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104
Signature	<i>Sheela Mohan-Peterson</i>
Date	01 - June - 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date indicated below:

Typed or printed	MELANIE LYONS
Signature	<i>Melanie Lyons</i>
Date	6-1-04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket: DX01040K3B

RECEIVED
CENTRAL FAX CENTER

JUN 01 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

In Re application of:

Jacqueline C. TIMANS, et al.

Application No.: 10/777,790

Filed: February 11, 2004

For: MAMMALIAN CYTOKINES;
RELATED REAGENTS

Examiner: unknown

Art Unit: 1646

Conf. No.: 3044

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 1, 2004

by:


MELANIE LYONSINFORMATION DISCLOSURE STATEMENT

Sir:

The materials as listed in the attached form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB08 listing references AA-BI.

All references listed on the attached form PTO/SB/08 have been previously cited either by Applicants or the Examiner in the parent application, U.S. Patent Application No. 10/000,776, filing date November 30, 2001, and copies should be available there. As such, these references will not be provided absent a specific request.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached PTO/SB/08 form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe no fee is required for filing this document; however, if such a fee is required, the Commissioner is hereby authorized to charge DNAX Research Institute Deposit account no. 04-1239.

Respectfully submitted,

Date: 01-June-2004

By: Sheela Mohan-Peterson
Sheela Mohan-Peterson
Reg. No. 41,201
Attorney for Applicants

Customer No. 28008
DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-1244
Facsimile No.: (650) 496-1200

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/777,790
				Filing Date	02/11/2004
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	1646
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	DX01040K3B

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AC	Paulina BALBAS and Francisco BOLIVAR, <i>Methods in Enzymology</i> , 185:14-37, 1990. "[3] Design and Construction of Expression Plasmid Vectors in <i>Escherichia coli</i> "		
	AD	J. Fernando BAZAN, et al., <i>NATURE</i> , 379:591, 15 February 1996. "A newly defined interleukin-1?"		
	AE	S.L. BEAUCAGE and M.H. CARUTHERS, <i>Tetrahedron Letters</i> , 22(20):1859-1862, 1981. "DEOXYNUCLEOSIDE PHOSPHORAMIDITES - A NEW CLASS OF KEY INTERMEDIATES FOR DEOXPOLYNUCLEOTIDE SYNTHESIS"		
	AF	M.F. BONALDO, et al., <i>GenBank</i> , Accession No. AA875330, 4 July 1999. Definition: "UI-R-E0-cn-h-10-0-UI.s1 UI-R-E0 Rattus norvegicus cDNA clone UI-R-E0-cn-h-10-0-UI 3' similar to gi 2947051 gb AC002425 HUAC002425 Homo sapiens Chromosome 16 BAC clone CIT987SK-A-575C2, complete sequence [Homo sapiens], mRNA sequence"		
	AG	Qi CHEN, et al., <i>NATURE</i> , 407:916-920, 19 October 2000. "Development of Th1-type immune responses require the type 1 cytokine receptor TCCR"		
	AH	Q. CHEN, et al., <i>GenBank</i> , Accession No. AF265242, 29 October 2000. Definition: "Homo sapiens type-1 T cell cytokine receptor mRNA, complete cds.."		
	AI	Andreas D. CHRIST, et al., <i>Gastroenterology</i> , 115:307-313, 1998. "An Interleukin 12-Related Cytokine is Up-regulated in Ulcerative Colitis but Not in Crohn's Disease"		
	AJ	Odile DEVERGNE, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 94:12041-12046, October 1997. "Epstein-Barr virus-induced gene 3 and the p35 subunit of Interleukin 12 form a novel heterodimeric hematopoietin"		
	AK	Odile DEVERGNE, et al., <i>GenBank</i> , Accession No. NM_005755, 29 June 2001. Definition: "Homo sapiens Epstein-Barr virus induced gene 3 (EBI3), mRNA."		
	AL	Alan D. ELBEIN, <i>Ann. Rev. Biochem.</i> , 56:497-534, 1987. "INHIBITORS OF THE BIOSYNTHESIS AND PROCESSING OF N-LINKED OLIGOSACCHARIDE CHAINS"		
	AM	Maurice K. GATELY, et al., <i>Annu. Rev. Immunol.</i> , 16:495-521, 1998. "THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses"		
	AN	Herve GROUX, et al., <i>J. Exp. Med.</i> , 184:19-29, July 1998. "Interleukin-10 Induces a Long-Term Antigen-specific Anergic State in Human CD4+ T Cells"		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-6199 (1-800-785-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/777,790
				Filing Date	02/11/2004
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	1646
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	DX01040K3B

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AO	Shin-ichi HASHIMOTO, et al., <u>Immunobiology</u> , 96(6):2206-2214, 15 September 2000. "Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression."		
	AP	Sten Eric W. JACOBSEN, <u>The Cytokine Handbook</u> , 3rd ed., Ch 13:365-367, Academic Press Ltd., 1996. "Interleukin-11: A Cytokine Signaling Through gp130 with Pleiotropic Effects and Potential Clinical Utility Within and Outside the Hematopoietic System"		
	AQ	Ross D. KING and Michael J.E. STERNBERG, <u>Protein Science</u> , 5:2298-2310, 1996. "Identification and application of the concepts important for accurate and reliable protein secondary structure prediction"		
	AR	Thomas A. KUNKEL, et al., <u>Methods in Enzymology</u> , 154:367-382, 1987. "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection"		
	AS	B.J. LOFTUS, et al., <u>GenBank</u> , Accession No. AC002544, 23 November 1999. Definition: "Homo sapiens Chromosome 16 BAC clone CIT987SK-A-761H5, complete sequence"		
	AT	LOFTUS, B.J., et al., "Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q", Database GenEmbl on STN, Locals HUAC002544 (GenEmbl, 23 November 1999).		
	AU	Verne A. LUCKOW and Max D. SUMMERS, <u>BIO/TECHNOLOGY</u> , 6:47-55, January 1988. "TRENDS IN THE DEVELOPMENT OF BACULOVIRUS EXPRESSION VECTORS"		
	AV	M. MARRA, et al., <u>GenBank</u> , Accession No. AA266872, 21 March 1997. Definition: "mz93a09.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone IMAGE:721000 5', mRNA sequence".		
	AW	NCI-CGAP, <u>GenBank</u> , Accession No. AI085007, 28 August 1998. Definition: "ow88d07.s1 Soares fetal liver spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:1653901 3' similar to contains element MER22 repetitive element ;, mRNA sequence"		
	AX	Saul B. NEEDLEMAN and Christian D. WUNSCH, <u>J. Mol. Biol.</u> , 48:443-453, 1970. "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins"		
	AY	Birgit OPPMANN, et al., <u>Immunity</u> , 13:715-725, November 2000. "Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12"		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 *Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.95. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/777,790
				Filing Date	02/11/2004
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	1646
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	DX01040K3B

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AZ	Patricia PARNET, <i>et al.</i> , <u>Journal of Biological Chemistry</u> , 271(8):3967-70, 1996. "IL-1Rrp Is a Novel Receptor-like Molecule Similar to the Type I Interleukin-1 Receptor and Its Homologues T1/ST2 and IL-1R AcP"		
	BA	Steven A. ROSENBERG, <u>Journal of Clinical Oncology</u> , 10(2):180-199, February 1992. "The Immunotherapy and Gene Therapy of Cancer"		
	BB	Burkhard ROST and Chris SANDER, <u>PROTEINS: Structure, Function and Genetics</u> , 19:55-72, 1994. "Combining Evolutionary Information and Neural Networks to Predict Protein Secondary Structure"		
	BC	Martin A. SCHWARTZ, <i>et al.</i> , <u>J. of Immunotherapy</u> , 16:95-104, 1994. "Stimulation of Cytokine Activity by Interleukin-10"		
	BD	Julie D. THOMPSON, <i>et al.</i> , <u>Nucleic Acids Research</u> , 25(24):4876-4882, 1997. "The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools"		
	BE	Giorgio TRINCHIERI, <u>Annu. Rev. Immunol.</u> , 13:251-276, 1995. "Interleukin-12: A Proinflammatory Cytokine With Immunoregulatory Functions That Bridge Innate Resistance And Antigen-Specific Adaptive Immunity"		
	BF	Giorgio TRINCHIERI, <u>Advances In Immunology</u> , 70:83-243, 1998. "Interleukin-12: A Cytokine at the interface of Inflammation and Immunity"		
	BG	Jean VIALLET and John D. MINNA, <u>Progress in Growth Factor Research</u> , 1:89-87, 1989. "Gastrin-Releasing Peptide (GRP, Mammalian Bombesin) In The Pathogenesis Of Lung Cancer"		
	BH	Slobodan VUKICEVIC, <i>et al.</i> , <u>Proc. Natl. Acad. Sci. USA</u> , 93:9021-26, August 1996. "Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (bone morphogenetic protein 7)"		
	BI	Meir WILCHEK, <i>et al.</i> , <u>Methods In Enzymology</u> , 104:3-55, 1984. "[1] affinity Chromatography"		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.